RxDoctor Payments Data

Anu Vellanki, MD

Cardiovascular Disease · Cumming, GANPI 1477783165

Payments from drug & device makers

$2,137in general payments, 2019–2025

Across 108 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$591
  • Amgen$278
  • Pfizer$213
  • E.r. Squibb & Sons, L.L.C.$121
  • Johnson & Johnson$114
  • Abiomed$74
  • plus $747 from 24 others

What the payments were for

  • Food & beverage$2,137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,137 in reported general payments places this provider in the 45th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$242,053
Medicare patients
1,779
Services billed
4,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban409$500,142
Repatha SureclickEvolocumab305$239,686
EntrestoSacubitril/Valsartan177$168,033
XareltoRivaroxaban94$102,506
FarxigaDapagliflozin Propanediol13$18,553
Praluent PenAlirocumab32$15,729
Repatha SyringeEvolocumab14$9,847
Ranolazine ErRanolazine92$7,486
Metoprolol Succinate463$6,006
Icosapent Ethyl21$5,496
Atorvastatin Calcium624$5,072
Midodrine Hcl43$4,715
Flecainide Acetate122$4,593
Dabigatran EtexilateDabigatran Etexilate Mesylate11$4,482
Ezetimibe149$3,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$213$500,142409 claims
NovartisEntresto$591$168,033177 claims
Johnson & JohnsonXarelto$114$102,50694 claims
AstraZenecaFarxiga$43$18,55313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →